---
license: cc-by-nc-4.0
pretty_name: "CSA — Clinical-Stage Asset Intelligence (Free Sample)"
task_categories:
  - tabular-classification
tags:
  - biotech
  - clinical-trials
  - finance
  - pharmaceuticals
  - catalyst-calendar
  - healthcare
size_categories:
  - n<1K
configs:
  - config_name: catalyst_calendar
    data_files: catalyst_calendar_sample.csv
    default: true
  - config_name: asset_master
    data_files: asset_master_sample.csv
---

# CSA — Clinical-Stage Asset Intelligence · Free Sample

**Clinical trials, FDA, and SEC — linked to the drug asset and the listed sponsor, with a
forward catalyst calendar.** This is a free 150-row sample of the nearest-term
catalysts; the full snapshot carries **2,103 forward catalysts** across
**139 listed sponsors** and **1,841 resolved assets**.

> **Data, not investment advice.** CSA is information, not a recommendation to buy, sell,
> or hold any security. Estimated catalyst dates (e.g. protocol primary-completion dates)
> routinely slip and are graded by confidence — verify anything material against the
> `source_url` on each row.

## What's inside

| File | Rows | What it is |
| :-- | :-- | :-- |
| `catalyst_calendar_sample.csv` | 150 | Nearest-term forward catalysts (2026-07-18 → 2027-09-01), 108 assets, 50 sponsors. |
| `asset_master_sample.csv` | 464 | The asset ↔ trial ↔ sponsor ↔ ticker rows behind them. |
| `*_sample.json` | — | The same tables as records-oriented JSON. |

### `catalyst_calendar_sample.csv`
`event_date` · `ticker` · `asset` · `event_type` (PDUFA / READOUT / …) · `event_window`
· `date_precision` · `confidence` · `source` (sec_8k / clinicaltrials) · `nct_id` · `source_url`.

### `asset_master_sample.csv`
`asset` · `nct_id` · `phase` · `status` · `primary_completion` · `conditions` · `arm_role`
· `sponsor_raw` · `company_name` · `ticker`.

## How it's built

- **Active-moiety resolution** keys each asset to its FDA-registered UNII set (GSRS), not
  fuzzy names — audited to **zero cross-molecule merges**.
- **Sponsor → listed ticker** through acquisitions, to the primary US listing.
- **Dual-channel catalysts**: SEC 8-K disclosure text + active late-phase
  ClinicalTrials.gov protocol readouts. Every row carries its source.

Sample scope: active, industry-sponsored, Phase 3 trials in cardiometabolic, oncology and
immunology. Asset names are normalized for readability; the sample is curated to
clinical-stage, single-sponsor assets.

## Sources & license

All primary sources are U.S. Government / public domain: **ClinicalTrials.gov**,
**openFDA**, **SEC EDGAR**, **GSRS/UNII**. This sample is released under **CC-BY-NC-4.0**
(free to use and share with attribution, not to re-sell). See `SAMPLE_LICENSE.md`.

## Get the full dataset

The complete, commercially-licensed snapshot (all 2,103 catalysts, CSV +
JSON, monthly editions + delta feed) → **https://csa.dataengineered.io**
· code: **https://github.com/CSA-pub/CSA-public** · contact: **https://csa.dataengineered.io/#contact**